Literature DB >> 8834901

Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells.

B B Barnett1, D F Smee, S M Malek, R W Sidwell.   

Abstract

Immunotoxins were constructed by linking immunoglobulins specific for murine cytomegalovirus (MCMV) to deglycosylated ricin A chain. Toxicities toward MCMV-infected and uninfected cells were determined by measuring the inhibition of protein synthesis following a 48-h exposure to immunotoxins commencing 24 h after infection. The 50% inhibitory concentrations ranged from 0.4 to 4 micrograms/ml for infected cells and from 22 to 120 micrograms/ml for uninfected cells. Selectivity indices ranged from 30 to 157. Control immunotoxins, which were constructed identically except that the immunoglobulin moiety had no specificity toward MCMV antigens, had 50% inhibitory concentrations of 50 and 100 micrograms/ml toward infected and uninfected cells, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834901      PMCID: PMC163137     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Ribosome inactivation by the toxic lectins abrin and ricin. Kinetics of the enzymic activity of the toxin A-chains.

Authors:  S Olsnes; C Fernandez-Puentes; L Carrasco; D Vazquez
Journal:  Eur J Biochem       Date:  1975-12-01

2.  Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients.

Authors:  G Laurent; J Pris; J P Farcet; P Carayon; H Blythman; P Casellas; P Poncelet; F K Jansen
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

3.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

Authors:  G V Quinnan; N Kirmani; A H Rook; J F Manischewitz; L Jackson; G Moreschi; G W Santos; R Saral; W H Burns
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

4.  Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin.

Authors:  K A Krolick; C Villemez; P Isakson; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

5.  Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A.

Authors:  F Stirpe; S Olsnes; A Pihl
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

6.  Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus.

Authors:  O L Laskin; D M Cederberg; J Mills; L J Eron; D Mildvan; S A Spector
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

7.  Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

Authors:  P E Thorpe; P M Wallace; P P Knowles; M G Relf; A N Brown; G J Watson; D C Blakey; D R Newell
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

8.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

Authors:  J P Sommadossi; R Carlisle
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

9.  Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).

Authors:  S L Walmsley; E Chew; S E Read; H Vellend; I Salit; A Rachlis; M M Fanning
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

10.  Value of necropsy in acquired immunodeficiency syndrome.

Authors:  M S Wilkes; A H Fortin; J C Felix; T A Godwin; W G Thompson
Journal:  Lancet       Date:  1988-07-09       Impact factor: 79.321

View more
  7 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.

Authors:  Eileen M Geoghegan; Hong Zhang; Prashant J Desai; Arya Biragyn; Richard B Markham
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.938

Review 3.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Antiviral Activity of Ribosome-Inactivating Proteins.

Authors:  Lucía Citores; Rosario Iglesias; José M Ferreras
Journal:  Toxins (Basel)       Date:  2021-01-22       Impact factor: 4.546

Review 5.  Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Authors:  Leonard Both; Ashley C Banyard; Craig van Dolleweerd; Edward Wright; Julian K-C Ma; Anthony R Fooks
Journal:  Vaccine       Date:  2013-01-29       Impact factor: 3.641

Review 6.  Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Authors:  Leonard Both; Ashley C Banyard; Craig van Dolleweerd; Edward Wright; Julian K-C Ma; Anthony R Fooks
Journal:  Pediatr Pol       Date:  2013-08-23

Review 7.  The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections?

Authors:  Carmen Giefing; Eszter Nagy; Alexander von Gabain
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.